A71

Phase II Data Of Medigen COVID-19 Vaccine, Reviewed And Published In The Lancet Respiratory Medicine

Retrieved on: 
Friday, October 15, 2021
Incidence, Immunoglobulin G, Severe acute respiratory syndrome coronavirus 2, Enterovirus, 1018, Method, GMP, MVC, Ageing, Infection, BAU, WHO, The Lancet, Seroconversion, Vaccine, MVC-COV1901, CpG, Emergency Use Authorization, A71, Fever, Pharmaceutical industry

TAIPEI, Oct. 15, 2021 /PRNewswire/ -- The Lancet Respiratory Medicine , one of the world's best-known peer-reviewed medical journals has published Medigen Vaccine Biologics (MVC) data from its MVC-COV1901 vaccine phase 2 clinical trial which demonstrates promising immunogenicity and safety profiles.

Key Points: 
  • TAIPEI, Oct. 15, 2021 /PRNewswire/ -- The Lancet Respiratory Medicine , one of the world's best-known peer-reviewed medical journals has published Medigen Vaccine Biologics (MVC) data from its MVC-COV1901 vaccine phase 2 clinical trial which demonstrates promising immunogenicity and safety profiles.
  • Participants were administered intramuscularly two doses of either MVC-COV1901 or placebo 28 days apart.
  • In both younger and older adults who received the MVC-COV1901 vaccine, almost all participants had seroconversion in younger adults and 995% in older adults.
  • About Medigen Vaccine Biologics Corp. (MVC)
    MVC is a biopharmaceutical company using cell-based technologies to develop novel vaccines and biosimilars.

Phase II Data Of Medigen COVID-19 Vaccine, Reviewed And Published In The Lancet Respiratory Medicine

Retrieved on: 
Friday, October 15, 2021
Incidence, Immunoglobulin G, Severe acute respiratory syndrome coronavirus 2, Enterovirus, 1018, Method, GMP, MVC, Ageing, Infection, BAU, WHO, The Lancet, Seroconversion, Vaccine, MVC-COV1901, CpG, Emergency Use Authorization, A71, Fever, Pharmaceutical industry

TAIPEI, Oct. 15, 2021 /PRNewswire/ -- The Lancet Respiratory Medicine , one of the world's best-known peer-reviewed medical journals has published Medigen Vaccine Biologics (MVC) data from its MVC-COV1901 vaccine phase 2 clinical trial which demonstrates promising immunogenicity and safety profiles.

Key Points: 
  • TAIPEI, Oct. 15, 2021 /PRNewswire/ -- The Lancet Respiratory Medicine , one of the world's best-known peer-reviewed medical journals has published Medigen Vaccine Biologics (MVC) data from its MVC-COV1901 vaccine phase 2 clinical trial which demonstrates promising immunogenicity and safety profiles.
  • Participants were administered intramuscularly two doses of either MVC-COV1901 or placebo 28 days apart.
  • In both younger and older adults who received the MVC-COV1901 vaccine, almost all participants had seroconversion in younger adults and 995% in older adults.
  • About Medigen Vaccine Biologics Corp. (MVC)
    MVC is a biopharmaceutical company using cell-based technologies to develop novel vaccines and biosimilars.